Safety and efficacy of non-viral aPD1-MSLN JL-lightning–CAR-T in advanced malignant mesothelioma in a phase I trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...

A Cancer Gene Therapy study reveals that MEOX2 promotes lung cancer progression while SMARCB1 acts as a tumor suppressor, ...

2025年5月8日，星汉德生物 (SCG)在荷兰阿姆斯特丹举行的2025年欧洲肝病年会 (EASL2025)上，公布了其自体HBV特异性TCR-T细胞疗法——SCG101的I期临床试验 ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...